The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
about
Computational neuropsychiatry - schizophrenia as a cognitive brain network disorderGlutamatergic drugs for schizophreniaSerine racemase binds to PICK1: potential relevance to schizophreniaNeuregulin 1 and susceptibility to schizophrenia.Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.Prenatal nutritional deficiency and risk of adult schizophreniaAugmentation treatment of psychotherapy for anxiety disorders with D-cycloserineElevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patientsTrace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsIn Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric DisordersA Review of Biomarkers in Mood and Psychotic Disorders: A Dissection of Clinical vs. Preclinical CorrelatesRole of nucleus accumbens glutamatergic plasticity in drug addictionRole of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesDrug models of schizophreniaAcetylsalicylic acid as an adjuvant therapy for schizophreniaMouse brain serine racemase catalyzes specific elimination of L-serine to pyruvateThe tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medicationsN-methyl-D-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder.The ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in miceInhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profileNegative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS studyDopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimeticsDisrupted-in-Schizophrenia 1 (DISC1) regulates spines of the glutamate synapse via Rac1Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseaseDysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoringNo effect of adjunctive, repeated-dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia.The NMDA receptor GluN2C subunit controls cortical excitatory-inhibitory balance, neuronal oscillations and cognitive function.Impaired prefrontal synaptic gain in people with psychosis and their relatives during the mismatch negativity.Early somatosensory processing in individuals at risk for developing psychoses.Thalamus and posterior temporal lobe show greater inter-network connectivity at rest and across sensory paradigms in schizophrenia.Potential primary roles of glial cells in the mechanisms of psychiatric disorders.Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion.ENU-mutagenesis mice with a non-synonymous mutation in Grin1 exhibit abnormal anxiety-like behaviors, impaired fear memory, and decreased acoustic startle response.Augmented gamma band auditory steady-state responses: support for NMDA hypofunction in schizophreniaComparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia.The environment and susceptibility to schizophrenia.Lamotrigine effects sensorimotor gating in WAG/Rij rats.
P2860
Q22241226-DC370603-AE71-40BB-9AE8-C73946048AB8Q24246163-82D23FBB-F66A-47F6-944C-A6FA520210F3Q24297355-B9854D86-DEDE-4D65-9229-39DABE873710Q24616921-62606304-427A-4ECC-9A7F-42AF5B80CDACQ24631189-C5D674A2-B3A9-4B82-AC0E-90036C23986EQ24643484-B46B0FB3-7F8C-41C3-A79D-7AC233F1ED15Q24684778-8153D022-D9D6-4F59-8AE4-A4E5E700E7F6Q24803969-C6C0586B-F04C-4173-80B4-7473566DD811Q26752602-9442196F-BC43-48B1-B2EF-07BD421BC537Q26769948-57C2F26B-5645-41CA-B1B8-337675A895BCQ26786354-79422C57-FCEB-4169-91E3-F7BC97D05BE1Q27013753-1E62D93E-68D0-42B0-B702-C7C730C32F75Q28072353-7C606C5F-DE43-4ADE-B644-FF9B85A747A2Q28084198-17A370AE-5BDE-45D7-A81D-C7E2D2AC8E17Q28200931-7244E249-4103-42BA-82A5-F861EADE1113Q28206399-17907147-7373-44B2-A44D-6226D131C6ECQ28270728-3E151EFF-AD40-4729-9B8E-36BCC4DB4204Q28285432-F8F33F4F-E55C-4B2B-942F-DCADA144590AQ28288084-D92407C7-C8D5-4BAB-B05A-DC482F7F7F4FQ28385659-C11DE511-ED23-492C-9F6D-A8CF93338BCBQ28389666-2F65F3DB-860D-4E0E-95D0-885D13F3B645Q28472479-5F3A1860-5DBD-4340-9EF1-707C7F1F7B5BQ28575182-F384303F-4FA0-468C-80B7-612330B0BEBFQ28583457-F7E0753B-41A3-485A-999B-2028F8B56E98Q28660933-DBB0F6A0-622D-4CD0-BFB8-52FAE8634F20Q28754716-0EEA492E-ED64-4587-8BEC-E35E8E03CDEDQ30360363-8EF2AF52-A923-4D86-8180-B78260C4D668Q30367844-341B45D5-F7DE-4B2B-9C0E-C4762D2B403CQ30384905-C250BC48-2E13-4675-8AB9-EE291A63D613Q30390556-A1E176D0-4153-477D-A7C3-36E73F4F2B47Q30404890-9F3F56C3-01FB-43E5-B769-583F219BCE3EQ30410688-1818BA08-DB1F-462F-A60F-8488E64938DCQ30428213-A9CC0C2D-E820-47DC-984A-B0E7CF04F752Q30439924-22DFF62C-5821-4CE0-B99B-D4AA405086E6Q30447828-0E44EBD2-9C67-4128-A673-A8B1ED3C73B5Q30453712-448A0D8B-8419-4828-AD23-B1097457B56EQ30454156-078DA70F-5A78-467E-9BDA-79C8756523B3Q30455798-E0FEF1EE-CC2E-400E-BFEC-8655404B0C9AQ30459929-6DE9827D-96C6-4691-83C8-4CBDE2A6ACD9Q30464975-520F1A6D-B0CF-4FF8-802B-5D7D4C455EEC
P2860
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@ast
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@en
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@nl
type
label
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@ast
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@en
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@nl
prefLabel
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@ast
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@en
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@nl
P1476
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.
@en
P2093
P304
P356
10.1176/APPI.AJP.158.9.1367
P407
P577
2001-09-01T00:00:00Z